在心力衰竭中拥堵的病理生理学:当代综述
Marko Kumric1, Tina Ticinovic Kurir1,2, Josko Bozic1
1Department of Pathophysiology, University of Split School of Medicine Split, Croatia.
Cardiac failure review
|October 25, 2024
概括
急性缺血性心力衰竭可能源于体积再分配,而不仅仅是液体过载. 了解血管内和血管外拥堵是有效的心力衰竭管理的关键.
科学领域:
- 心脏病学 心脏病学
- 内部医学 内部医学
- 病理生理学 病理生理学
背景情况:
- 急性不补偿性心力衰竭 (ADHF) 是全球住院的主要原因.
- 拥堵是ADHF的主要驱动因素,通常仅被错误地归因于体积过载.
- 新出现的证据表明,体积再分配,而不仅仅是积累,可以导致ADHF.
研究的目的:
- 为了澄清ADHF中血管内和血管外拥堵之间的病理生理差异.
- 探索这些拥堵类型与临床,生化和成像标志物之间的关系.
- 突出区分拥堵表型的临床意义,以进行量身定制的管理.
主要方法:
- 文献综述专注于心力衰竭拥堵病理生理学.
- 对区分血管内和血管外拥堵的研究进行分析.
- 拥堵类型与诊断指数的相关性.
主要成果:
- 由于体积再分配,ADHF可以发生在没有显著的整体流体过载的情况下.
- 血管内和血管外塞存在重叠和动态特征.
- 临床,生化和成像发现可能有助于区分拥堵类型.
结论:
- 在优化ADHF治疗策略方面,区分血管内和血管外拥堵至关重要.
- 需要进一步的研究来完善对拥堵表型的诊断标准.
- 了解体积再分配为ADHF病原体提供了新的视角.
更多相关视频
相关概念视频
Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Heart Failure II: Pathophysiology
1
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1
Heart Failure V: Medical Management
1
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
1
Heart Failure I: Introduction
1
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
1
Imbalances in Cardiac Output
1.3K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.3K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
394
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
394


